SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-202617
Filing Date
2022-07-27
Accepted
2022-07-27 07:08:03
Documents
14
Period of Report
2022-07-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d338727d8k.htm   iXBRL 8-K 30159
2 EX-10.1 d338727dex101.htm EX-10.1 88342
3 EX-99.1 d338727dex991.htm EX-99.1 5680
  Complete submission text file 0001193125-22-202617.txt   269737

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apls-20220726.xsd EX-101.SCH 2857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20220726_lab.xml EX-101.LAB 17236
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20220726_pre.xml EX-101.PRE 10813
8 EXTRACTED XBRL INSTANCE DOCUMENT d338727d8k_htm.xml XML 3202
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 221108829
SIC: 2834 Pharmaceutical Preparations